General Information of This Metabolic Reaction (MR) (ID: MR013214)
Formula
ES
SVG example
Reactant Remdesivir Nucleoside Monophosphate Product GS-441524
Reactant Info Product Info
Metabolic Enzyme Esterases (ES) DME Info
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Produce The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR009118 GS-441524 GS-441524-MP Unclear - Unclear GS-441524 [1]
MR014047 Remdesivir Alanine Metabolite (Ala-Met; GS-704277) Remdesivir Nucleoside Monophosphate Unclear Remdesivir [2]
MR013219 Remdesivir M1 Remdesivir Nucleoside Monophosphate Unclear Remdesivir [2]
MR013212 Remdesivir Alanine Metabolite (Ala-Met; GS-704277) Remdesivir Nucleoside Monophosphate Oxidation - Deamination Remdesivir [3]
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR009119 GS-441524-MP GS-441524-DP Unclear - Unclear GS-441524 [1]
MR014048 Remdesivir Nucleoside Monophosphate Remdesivir Nucleoside Triphosphate Conjugation - Phosphorylation Remdesivir [4]
MR013213 Remdesivir Nucleoside Monophosphate Remdesivir Nucleoside Triphosphate Conjugation - Phosphorylation Remdesivir [3]
Other MR(s) Related to The Product of This MR
Other MR(s) That Produce The Product of This MR
MR ID Reactant Product MR Type Related Drug REF
MR013220 Remdesivir GS-441524 Unclear Remdesivir [5]
References
1 Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside
2 Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir
3 Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19
4 Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19
5 Removal of Remdesivir's Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.